| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H16N2O6 |
| Molecular Weight | 356.3294 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(=O)C2=C(C(COC3=CC=C(C=C3)[N+]([O-])=O)=C(C)N2C)C1=O
InChI
InChIKey=IBLWSLZYYZHSRG-UHFFFAOYSA-N
InChI=1S/C18H16N2O6/c1-10-13(9-26-12-6-4-11(5-7-12)20(23)24)16-17(19(10)2)14(21)8-15(25-3)18(16)22/h4-8H,9H2,1-3H3
ES936 is a potent mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 (NQO1), that exhibited potent growth inhibition effects against human pancreatic cancer cell lines. It was also shown, that drug can stimulate DNA synthesis in some cells through a mechanism involving p38 MAPK.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
Sample Use Guides
ES936 (100 nM) inhibits more than 95% of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity within 30 min and is stable in complete media at this concentration for a minimum of 2 h. The duration of inhibition is cell line-specific because a new protein must be generated for resumption of activity. ES936 abrogates the toxicity of streptonigrin, with greater effects seen in cell lines expressing higher levels of NQO1. ES936 does not inhibit other cellular reductases, nor does it alter cellular levels of acid-soluble thiols. Some evidence of DNA strand breaks was observed at the concentrations of ES936 required for the inhibition of NQO1 activity. It was proposed the use of ES936 (100 nM) as a mechanism-based inhibitor of NQO1 in cellular systems and for use as a component of the routine activity assay for NQO1.
ACTIVE MOIETY
